You just read:

Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2

News provided by

Neurotech Pharmaceuticals, Inc.

Feb 12, 2019, 09:36 ET